Treatment of chronic ulcers
The present invention provides a pharmaceutical formulation comprising LL-37 or a pharmaceutically-acceptable salt thereof and one or more pharmaceutically-acceptable diluent or carrier system, for use in a method of treatment of a chronic ulcer wound (such as a hard-to-heal venous leg ulcer or a diabetic foot ulcer), which method comprises: (a) topical application of the formulation to the ulcer; followed by (b) application of a dressing, and wherein the application of the formulation provides for a dose of LL-37 at the wound site that is below about 80 μg of LL-37 applied per cm 2 of wound area, and/or below about 26.7 μg of LL-37 applied per cm 2 of wound area, per day of treatment.
1. A method of treating a chronic ulcer, wherein said method comprises:
(a) topically applying to said chronic ulcer a pharmaceutical formulation, wherein the pharmaceutical formulation is an aqueous solution comprising LL-37 or a pharmaceutically-acceptable salt thereof, wherein the pharmaceutical formulation comprises one thickening agent being polyvinyl alcohol; followed by
(b) topically applying a dressing to said chronic ulcer;
wherein the dose of LL-37 applied per cm 2 of wound area is between about 1 μg/cm 2 and about 70 μg/cm 2 , and wherein the pharmaceutical formulation has a viscosity in the range of about 2 and about 10 Pa·s.
2. The method as claimed in claim 1 , wherein the dose of LL-37 applied per cm 2 of wound area is between about 5 μg/cm 2 and about 60 μg/cm 2 .
3. A method of treating a chronic ulcer, wherein said method comprises:
(a) topically applying to said chronic ulcer a pharmaceutical formulation, wherein the pharmaceutical formulation is an aqueous solution comprising LL-37 or a pharmaceutically-acceptable salt thereof, wherein the pharmaceutical formulation comprises one thickening agent being polyvinyl alcohol; followed by
(b) topically applying a dressing to said chronic ulcer; wherein the dose of LL-37 applied per cm 2 of wound area is between about 0.3 μg/cm 2 and about 23.3 μg/cm 2 per day of treatment, and wherein the pharmaceutical formulation has a viscosity in the range of about 2 and about 10 Pa·s.
4. The method as claimed in claim 3 , wherein the dose is between about 1.6 μg/cm 2 and about 20 μg/cm 2 per day of treatment.
5. The method as claimed in claim 1 , wherein the chronic ulcer is a venous leg ulcer.
6. The method as claimed in claim 1 , wherein the chronic ulcer is a diabetic foot ulcer.
7. The method as claimed in claim 2 , wherein the chronic ulcer is a venous leg ulcer.
8. The method as claimed in claim 2 , wherein the chronic ulcer is a diabetic foot ulcer.
9. The method as claimed in claim 3 , wherein the chronic ulcer is a venous leg ulcer.
10. The method as claimed in claim 3 , wherein the chronic ulcer is a diabetic foot ulcer.
11. The method as claimed in claim 4 , wherein the chronic ulcer is a venous leg ulcer.
12. The method as claimed in claim 4 , wherein the chronic ulcer is a diabetic foot ulcer.
13. A method of treating a chronic ulcer, wherein said method comprises:
(a) topically applying to said chronic ulcer a pharmaceutical formulation, wherein the pharmaceutical formulation is an aqueous solution consisting of i) LL-37 or a pharmaceutically-acceptable salt thereof; ii) polyvinyl alcohol; iii) a buffer; iv) water; and v) optionally one or more pharmaceutically acceptable excipients;
wherein the dose of LL-37 applied per cm 2 of wound area is between about 1 μg/cm 2 and about 70 μg/cm 2 ; wherein the pharmaceutical formulation is a viscous liquid having a viscosity in the range of about 2 and about 10 Pa's; and
wherein the pharmaceutically acceptable excipient is selected from a preservative, an antioxidant, a tonicity modifying agent and a coloring agent.
14. A method of treating a chronic ulcer, wherein said method comprises:
(a) topically applying to said chronic ulcer an aqueous pharmaceutical formulation, wherein the pharmaceutical formulation is an aqueous solution consisting of i) LL-37 or a pharmaceutically-acceptable salt thereof; ii) polyvinyl alcohol; iii) a buffer; iv) water; and v) optionally one or more pharmaceutically acceptable excipients; followed by
(b) topically applying a dressing to said chronic ulcer;
wherein the dose of LL-37 is between about 0.3 μg/cm 2 and about 23.3 μg/cm 2 per day of treatment; wherein the pharmaceutical formulation is a viscous liquid having a viscosity in the range of about 2 and about 10 Pa·s; and
wherein the pharmaceutically acceptable excipient is selected from a preservative, an antioxidant, a tonicity modifying agent and a coloring agent.